BioCentury | Feb 25, 2013
Company News

AntriaBio management update

...formerly CEO of AeroSurgical Ltd.; and Sankaram Mantripragada as CSO, formerly VP of R&D at PR Pharmaceuticals Inc. WIR...
BioCentury | Jan 14, 2013
Company News

AntriaBio, PR Pharma deal

...disclose details, and PR Pharmaceuticals could not be reached. AntriaBio Inc. , Menlo Park, Calif. PR Pharmaceuticals Inc....
BioCentury | Feb 16, 2009
Company News

PR Pharma cardiovascular news

...drug delivery assets to SurModics Inc. (NASDAQ:SRDX, Eden Prairie, Minn.) (see BioCentury, Nov. 10, 2008). PR Pharmaceuticals Inc....
BioCentury | Nov 10, 2008
Company News

PR Pharma, SurModics deal

...million in milestones. SurModics also will take over PR Pharma's drug delivery partnerships and will co-develop PR Pharma's...
...undisclosed upfront payment and is eligible for milestones and royalties. PR Pharma is responsible for commercialization. PR Pharma's...
...a long-acting injectable formulation of octreotide in preclinical testing to treat diabetic retinopathy and acromegaly. PR Pharmaceuticals Inc....
BioCentury | Oct 20, 2008
Strategy

Shire's ophthalmics play

...of both compounds, which are delivered via intravitreal injection. In April, Jerini partnered to use PR Pharmaceuticals Inc....
...PDL BioPharma Inc. (NASDAQ: PDL I), Redwood City, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. PR Pharmaceuticals Inc....
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...to treat dry eye in postmenopausal women Apr 08 Jerini/PR Pharmaceuticals Undisclosed Partners will use PR Pharma's...
BioCentury | Apr 14, 2008
Company News

Jerini, PR Pharma deal

...PR Pharma and Jerini's Jerini Ophthalmic Inc. subsidiary will use PR Pharma's drug delivery technologies to develop...
...to develop sustained-release formulations of Jerini's JSM6427 and JPE-1375 to treat age-related macular degeneration (AMD). PR Pharma...
...JPE-1375 is a complement C5a receptor antagonist in preclinical development. Jerini AG (Xetra:JI4), Berlin, Germany PR Pharmaceuticals Inc....
BioCentury | Apr 3, 2006
Clinical News

2-methoxyestradiol: Phase I started

...trial in 50 healthy volunteers to evaluate subcutaneous doses of sustained-release injectable formulation of PulmoLAR. PR Pharmaceuticals Inc....
BioCentury | Jan 16, 2006
Company News

OSI, PR Pharma deal

...with PR Pharma to develop a sustained-release formulation of Macugen pegaptanib using PR Pharma's ProPhase encapsulation technology. PR Pharma...
...preclinical and clinical manufacturing. OSIP is responsible for clinical development and has exclusive commercialization rights. PR Pharma...
...upfront payment and is eligible for milestones and royalties. OSI Pharmaceuticals Inc. (OSIP), Melville, N.Y. PR Pharmaceuticals Inc....
BioCentury | Jan 12, 2006
Company News

OSI pursuing sustained-release Macugen

...Collins, Colo.) to develop a sustained-release formulation of Macugen pegaptanib using PR Pharma's ProPhase encapsulation technology. PR Pharma...
...preclinical and clinical manufacturing. OSIP is responsible for clinical development and has exclusive commercialization rights. PR Pharma...
Items per page:
1 - 10 of 12
BioCentury | Feb 25, 2013
Company News

AntriaBio management update

...formerly CEO of AeroSurgical Ltd.; and Sankaram Mantripragada as CSO, formerly VP of R&D at PR Pharmaceuticals Inc. WIR...
BioCentury | Jan 14, 2013
Company News

AntriaBio, PR Pharma deal

...disclose details, and PR Pharmaceuticals could not be reached. AntriaBio Inc. , Menlo Park, Calif. PR Pharmaceuticals Inc....
BioCentury | Feb 16, 2009
Company News

PR Pharma cardiovascular news

...drug delivery assets to SurModics Inc. (NASDAQ:SRDX, Eden Prairie, Minn.) (see BioCentury, Nov. 10, 2008). PR Pharmaceuticals Inc....
BioCentury | Nov 10, 2008
Company News

PR Pharma, SurModics deal

...million in milestones. SurModics also will take over PR Pharma's drug delivery partnerships and will co-develop PR Pharma's...
...undisclosed upfront payment and is eligible for milestones and royalties. PR Pharma is responsible for commercialization. PR Pharma's...
...a long-acting injectable formulation of octreotide in preclinical testing to treat diabetic retinopathy and acromegaly. PR Pharmaceuticals Inc....
BioCentury | Oct 20, 2008
Strategy

Shire's ophthalmics play

...of both compounds, which are delivered via intravitreal injection. In April, Jerini partnered to use PR Pharmaceuticals Inc....
...PDL BioPharma Inc. (NASDAQ: PDL I), Redwood City, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. PR Pharmaceuticals Inc....
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...to treat dry eye in postmenopausal women Apr 08 Jerini/PR Pharmaceuticals Undisclosed Partners will use PR Pharma's...
BioCentury | Apr 14, 2008
Company News

Jerini, PR Pharma deal

...PR Pharma and Jerini's Jerini Ophthalmic Inc. subsidiary will use PR Pharma's drug delivery technologies to develop...
...to develop sustained-release formulations of Jerini's JSM6427 and JPE-1375 to treat age-related macular degeneration (AMD). PR Pharma...
...JPE-1375 is a complement C5a receptor antagonist in preclinical development. Jerini AG (Xetra:JI4), Berlin, Germany PR Pharmaceuticals Inc....
BioCentury | Apr 3, 2006
Clinical News

2-methoxyestradiol: Phase I started

...trial in 50 healthy volunteers to evaluate subcutaneous doses of sustained-release injectable formulation of PulmoLAR. PR Pharmaceuticals Inc....
BioCentury | Jan 16, 2006
Company News

OSI, PR Pharma deal

...with PR Pharma to develop a sustained-release formulation of Macugen pegaptanib using PR Pharma's ProPhase encapsulation technology. PR Pharma...
...preclinical and clinical manufacturing. OSIP is responsible for clinical development and has exclusive commercialization rights. PR Pharma...
...upfront payment and is eligible for milestones and royalties. OSI Pharmaceuticals Inc. (OSIP), Melville, N.Y. PR Pharmaceuticals Inc....
BioCentury | Jan 12, 2006
Company News

OSI pursuing sustained-release Macugen

...Collins, Colo.) to develop a sustained-release formulation of Macugen pegaptanib using PR Pharma's ProPhase encapsulation technology. PR Pharma...
...preclinical and clinical manufacturing. OSIP is responsible for clinical development and has exclusive commercialization rights. PR Pharma...
Items per page:
1 - 10 of 12